Hyperfine stock rises after FDA clearance for enhanced stroke imaging tech

Investing.com -- Western Digital Corp. (NASDAQ:WDC) stock rose 1.7% Monday following the announcement of its inclusion in the Nasdaq-100 Index as part of the annual reconstitution.

The data storage company was among six firms added to the influential index, which tracks the performance of the 100 largest non-financial companies listed on the Nasdaq Stock Market. Other additions included Seagate Technology Holdings (NASDAQ:STX), which gained 2%, Alnylam Pharmaceuticals (NASDAQ:ALNY), up 0.9%, Ferrovial SE (NASDAQ:FER), rising 0.7%, Insmed (NASDAQ:INSM), up 1.2%, and Monolithic Power Systems (NASDAQ:MPWR), which climbed 1.3%.

The changes will take effect prior to market open on Monday, December 22, 2025, according to Nasdaq's announcement. The reconstitution occurs annually in December, coinciding with the quadruple witch expiration Friday of the quarter.

Six companies will be removed from the index as part of the rebalancing: Biogen (NASDAQ:BIIB), CDW Corporation (NASDAQ:CDW), GlobalFoundries (NASDAQ:GFS), lululemon athletica (NASDAQ:LULU), ON Semiconductor (NASDAQ:ON), and The Trade Desk (NASDAQ:TTD). Lululemon shares fell 1.1% following the news.

The Nasdaq-100 Index is widely tracked by investors, with more than 200 products based on the index representing over $600 billion in assets under management globally. The most prominent of these is the Invesco QQQ Trust (NASDAQ:QQQ), which aims to track the index's performance before expenses.

Investing.com -- Doximity’s recent share price weakness looks out of step with a business that is seeing stronger engagement, rising ad demand and expanding use of its workflow tools, Morgan Stanley said as it upgraded the healthcare platform to Overweight.

Stock’s roughly 30% drop since early November has created an attractive entry point, particularly as Doximity’s guidance and consensus estimates remain conservative. Doximity shares are down about 18% year to date despite higher revenue and EBITDA estimates for calendar 2025.

Morgan Stanley raised its revenue growth forecasts for fiscal 2026 to 2028 and lifted its EBITDA estimates across the same period amid deeper integration of Doximity’s tools into clinicians’ daily routines. Brokerage also raised its price target to $65, about 45% upside.

Analysts said Doximity has moved beyond being a platform doctors check at the end of the day, as products such as Dialer, messaging, fax, email and AI tools including Doximity Scribe and DoxGPT are increasingly used throughout the workday.

Time spent on the platform is rising even as growth in daily active users moderates, which means there is higher engagement per user.

That engagement is translating into monetisation, Morgan Stanley said. Doximity remains a leading destination for pharmaceutical digital advertising targeted at healthcare professionals, benefiting from verified user data and strong targeting.

Ad agencies told the bank that HCP-focused digital ad budgets are growing 5% to 15% a year, with Doximity capturing a growing share as spending shifts away from TV and field sales.

Concerns around rising competition from OpenEvidence appear overdone, the analysts said. While OpenEvidence has introduced features similar to Doximity’s dialer, Morgan Stanley said there is limited evidence of disruption so far, and questions remain over how rivals can scale compliant pharma advertising.

The bank also highlighted Doximity’s balance sheet, with $878m in cash, no debt and an estimated $1bn in cumulative free cash flow through fiscal 2028, giving the company flexibility for buybacks and acquisitions.

Morgan Stanley said the stock’s underperformance does not reflect improving fundamentals or longer-term growth opportunities tied to workflow tools and AI-driven engagement.

Investing.com -- Intel (NASDAQ:INTC) stock rose 1.25% Monday amid broader strength in the technology sector and following reports that the chipmaker is nearing a $1.6 billion acquisition of AI chip startup SambaNova Systems.

According to a Bloomberg report published Friday, Intel is in advanced talks to purchase the Palo Alto, California-based company in a deal that could materialize as soon as next month. The potential acquisition includes SambaNova’s debt, according to people familiar with the matter who asked not to be identified.

While discussions are reportedly at an advanced stage, the terms and timing could still change. SambaNova, which has signed term sheets with other potential financial investors, might also pursue alternative options, the sources indicated.

The potential acquisition comes as Intel seeks to strengthen its position in the rapidly growing artificial intelligence chip market, where competitors like Nvidia have established dominant positions. SambaNova develops AI accelerators designed to handle complex machine learning workloads.

Representatives for both Intel and SambaNova declined to comment on the potential deal when contacted by Bloomberg.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.